1 mon grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs

2  which is characterized by a large number of acneiform and papular skin lesions, with very few or no

3 in other follicular pathologies, such as the acneiform conditions, are inadequately explored and must

4 g (rash) and two of five patients at 350 mg (acneiform dermatitis and fatigue/decreased Eastern Coope

5 e diarrhoea in 83 (93%) patients, dermatitis acneiform in 69 (78%) patients, dry skin in 39 (44%) pat

6 lated adverse events were rash or dermatitis acneiform (n=165; 80%) and diarrhoea (87; 42%), most of

7 lated adverse events were rash or dermatitis acneiform (n=80; 82%) and diarrhoea (44; 45%), most of w

8 d with 10-300 lesions that were a mixture of acneiform, papular, nodular, and ulcerated types.

9 xed were fatigue (33 [11%] of 292 patients), acneiform rash (31 [11%]), dyspnoea (29 [10%]), and decr

10 2%] patients on dacomitinib vs no controls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (

11 vents were diarrhoea (83 patients, 64%), non-acneiform rash (77 patients, 60%), liver enzyme abnormal

12              The most common toxicities were acneiform rash (79%) and diarrhea (69%).

13                        With the exception of acneiform rash and infusion reactions, the incidence of

14  be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treat

15                                           An acneiform rash occurred in 82.9% of patients; grade 3 ra

16              Mild to moderate (grade 1 to 2) acneiform rash occurred in a majority of patients; no gr

17 icantly improved in those who experienced an acneiform rash of at least grade 2 severity compared wit

18  (EGFR) antibody therapy often experience an acneiform rash of uncertain etiology in skin regions ric

19 both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of ce

20              The most common toxicities were acneiform rash, diarrhea, hand reaction, dyspepsia, and

21 effects associated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomat

22                   The principal toxicity, an acneiform rash, occurred in 68%, 95%, 87%, and 100% of p